The researchers found that by combining a common antibiotic called meropenem with a light-activated compound called methylene blue, they could effectively kill antibiotic-resistant bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii, without affecting the growth of beneficial bacteria.
The key discovery was that methylene blue, when combined with meropenem, creates a combination known as photodynamic therapy, which uses light to activate the antibiotic and make it more effective against bacteria.
The team tested their approach on antibiotic-resistant bacteria and found that the combination of meropenem and methylene blue, activated by light, killed 99.9% of the bacteria within 10 minutes. This effect was not seen with either compound alone, highlighting the synergistic effect of the combination therapy.
The researchers also tested the approach in a mouse infection model and found that the combination therapy effectively reduced the number of antibiotic-resistant bacteria in the bloodstream.
The study's findings offer a promising new strategy to combat antibiotic resistance, which has become a major global health concern, threatening the effectiveness of commonly used antibiotics. This combination approach using antibiotics and light therapy could potentially be developed into a new treatment for antibiotic-resistant infections, providing a more targeted and effective way to combat these superbugs.
